Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Deals

Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland

Fineline Cube Dec 19, 2022

China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider,...

Company Deals

InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao

Fineline Cube Dec 19, 2022

InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen,...

Company

Novartis China Establishes Health Development Fund in Boao Lecheng

Fineline Cube Dec 19, 2022

Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...

Company Drug

Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC

Fineline Cube Dec 16, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...

Company Deals

XingImaging and Mitro Biotech Partner for Contract Research Services in China

Fineline Cube Dec 16, 2022

US-based XingImaging LLC and China-based Mitro Biotech Co., Ltd have announced a partnership to provide...

Company Drug

Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303

Fineline Cube Dec 16, 2022

China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...

Company Policy / Regulatory

WuXi Biologics’ Shanghai Subsidiary Removed from US UVL

Fineline Cube Dec 16, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Policy / Regulatory

Liaoning Publishes Fourth Round of Volume-Based Procurement Winning Bids

Fineline Cube Dec 16, 2022

The Liaoning drug and medical consumables centralized procurement website has published the fourth round of...

Company Deals

Cryofocus Medtech Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 16, 2022

China-based Cryofocus Medtech (Shanghai) Co., Ltd, a minimally invasive interventional cryotherapy device maker, is set...

Company Medical Device

NMPA Approves SonoScape and Acoustic Life’s Intravascular Ultrasound Products

Fineline Cube Dec 16, 2022

The National Medical Products Administration (NMPA) has approved Chinese firms SonoScape Medical Corp’s intravascular ultrasound...

Company Drug

Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis

Fineline Cube Dec 15, 2022

German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...

Drug

Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China

Fineline Cube Dec 15, 2022

Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...

Company Medical Device

Acotec Scientific’s NEO-Skater Balloon Approved by NMPA for Intracranial Vessels

Fineline Cube Dec 15, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approval from the National...

Company Drug

Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial

Fineline Cube Dec 15, 2022

China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...

Company Drug

Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC

Fineline Cube Dec 15, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...

Company Drug

Henlius Biotech Initiates Phase I Trial for HLX60 in Australia

Fineline Cube Dec 15, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...

Company Deals

China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China

Fineline Cube Dec 15, 2022

China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer...

Company Medical Device

Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter

Fineline Cube Dec 15, 2022

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Innovent Biologics Collaborates with LG Chem for Tigulixostat in China

Fineline Cube Dec 15, 2022

China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...

Deals Drug

Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine

Fineline Cube Dec 15, 2022

China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...

Posts pagination

1 … 638 639 640 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.